Blood levels of beta-amyloid 42 rose by an average of 35% in healthy adults who spent 40 minutes on a gently vibrating mattress while taking two nitric-oxide-releasing sublingual pills. That result, from Vesa Kiviniemi of the University of Oulu and colleagues, is the study’s central finding, and it needs immediate context to make sense.
Beta-amyloid 42 is a protein involved in normal neuronal signaling, but when it misfolds and clumps inside the brain tissue, those aggregates are associated with Alzheimer’s disease.
The Brain Has a Waste-Disposal Network, and This Study Tried to Tune It
The glymphatic system clears metabolic waste through fluid channels around brain blood vessels, and the researchers aimed to amplify that process.
The glymphatic system is a network of fluid-filled channels surrounding brain blood vessels that transports metabolic waste out of the brain. It works partly through the rhythmic widening and narrowing of those vessels, which pulses waste-laden fluid toward disposal.
Kiviniemi’s proposed mechanism runs on two tracks. Gentle whole-body vibration may activate the Piezo1 protein in vessel-wall muscle cells, a link identified in prior animal research. Nitric oxide promotes vessel dilation, and together, the researchers suggest, both effects amplify the pulsation that drives glymphatic clearance.
When participants received only the mattress or only the pills, the apparent effect on fluid movement was less than half what the combined intervention produced.
Higher Blood Levels Could Mean Export. Or Something Else Entirely.
An alternative explanation from an outside researcher complicates the team’s interpretation.
Kiviniemi’s team interprets the rise in circulating beta-amyloid 42 as evidence that more of the protein moved from the brain into the bloodstream. Christopher Brown of the University of Southampton offered a different reading: the liver may simply have broken down the protein more slowly than usual, which would also produce a higher blood concentration without any change in brain clearance.
Brown suggested that injecting tracers into cerebrospinal fluid to track glymphatic flow directly could help reduce that uncertainty in future work.
The Study Was Small, Healthy, and Short
None of the 29 participants had an Alzheimer’s diagnosis or diagnosed cognitive impairment.
Six participants reported mild nausea or headache after the combined intervention. Because the trial did not include a placebo pill, separating genuine side effects from expectation is not currently possible, and future trials are expected to add that control.
This Is Not an Alzheimer’s Treatment
The study measured an acute biomarker change in healthy adults, not a reduction in disease symptoms or risk.
No reduction in Alzheimer’s symptoms, brain amyloid plaques, or dementia risk was measured. A clinically meaningful therapy would need reproducible effects in people with mild cognitive impairment or Alzheimer’s disease. It would also require sustained changes in brain pathology and measurable gains in memory or problem-solving.
Nitric Oxide Lowers Blood Pressure. Do Not Try This at Home.
Kiviniemi warned that the blood-pressure effect of nitric oxide carries a serious risk for some people.
Kiviniemi cautioned that nitric oxide can lower blood pressure, and for anyone who already has low blood pressure, taking a nitric-oxide-releasing pill could cause loss of consciousness. Nitric-oxide supplements and high-dose carbon-dioxide inhalation should not be attempted outside a clinical setting, and this intervention does not establish that any commercial product is safe or effective.
Other Researchers Are Chasing the Same System
Glymphatic research extends well beyond vibrating mattresses.
Other experimental approaches under investigation include ultrasound, pink noise, and intermittent inhalation of high concentrations of carbon dioxide. Brown noted that pursuing multiple strategies improves the odds that at least one eventually produces a clinically useful tool.
The Next Trial Will Test People Who Actually Have the Disease
Results from a planned 60-person study could clarify whether the effect holds in the population that needs it most.
Kiviniemi’s team hopes to test the combined approach in 60 people with mild cognitive impairment or Alzheimer’s disease. If that trial produces a positive result, a longer study lasting several months could assess whether repeated treatment affects memory and problem-solving.
